Articles tagged with: Imnovid

News»

[ by and | Jun 7, 2010 12:33 am | 3 Comments ]
Pomalidomide-Dexamethasone Combination Has Therapeutic Benefit For Heavily Pre-Treated Multiple Myeloma Patients (ASCO 2010)

Results from an ongoing Phase 2 clinical trial suggest that pomalidomide (Pomalyst) in combination with dexamethasone (Decadron) is effective and well-tolerated in patients who are resistant (refractory) to previous myeloma treatment with both Revlimid (lenalidomide) and Velcade (bortezomib). The findings were presented by Dr. Martha Lacy of the Mayo Clinic at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Saturday.

“We found the pomalidomide-dexamethasone regimen has significant activity in Revlimid- and Velcade-refractory myeloma,” said Dr. Lacy.

Pomalidomide is a new therapy being developed by …

Read the full story »

News»

[ by | Nov 23, 2009 4:18 pm | 3 Comments ]
Single-Agent Actimid And Combination Actimid-Dexamethasone Regimens Are Promising Treatments For Relapsed Myeloma (ASH 2009)

At the upcoming meeting of the American Society of Hematology (ASH), there will be several presentations about Actimid (pomalidomide). Actimid, a new drug being developed by Celgene Corporation as a treatment for multiple myeloma, is a molecular derivative of thalidomide (Thalomid).

Actimid As A Combination Therapy With Dexamethasone

One of the ASH presentations will show that the combination regimen of Actimid and low-dose dexamethasone (Decadron) is an effective treatment for relapsed multiple myeloma.

Actimid was tested in combination with dexamethasone in 34 patients with relapsed myeloma following therapy with

Read the full story »

News»

[ by | Sep 4, 2009 9:55 pm | One Comment ]
Combination Actimid And Dexamethasone Regimen Is Promising For Relapsed And Refractory Myeloma Patients

The Journal of Clinical Oncology has reported that a combination regimen of Actimid (pomalidomide) and low-dose dexamethasone (Decadron) in a Phase 2 clinical trial was highly effective in the treatment of relapsed and refractory multiple myeloma patients.

Actimid belongs to a class of therapeutic agents called immunomodulatory drugs (IMiDs), which are molecular analogs of thalidomide (Thalomid). Thalidomide acts on myeloma tumors by inhibiting the growth of new blood vessels. In addition to this mechanism, IMiDs prevent the development of abnormal tissue masses called neoplasms and induce programmed cell death. …

Read the full story »

Resources, Treatments Under Development»

[ by | Oct 15, 2008 8:00 am | 4 Comments ]
Pomalidomide (Pomalyst, CC-4047, Actimid)
Brand Name:  
Generic Name: pomalidomide
Code Name: CC-4047, Actimid
Company: Celgene
FDA Clinical Phase: 1/2

Description:

Pomalidomide (new articles, forum discussions) is an immunomodulatory agent (a drug that affects the immune system) that encourages a patient’s immune system to attack and destroy myeloma cells.
Read the full story »